As an extension to the theme of targeting B cell autoimmune indications with BTK inhibitors, four disease indications thought to be driven by autoantibodies (MS, PV, ITP, and SCU) have been or currently are being targeted in clinical trials. This evidence concerns the gene BTK and myeloid sarcoma.